AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9133133
Drug: Oral polyethylene
RxNorm normalized name: polyethylenes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral polyethylene glycol solution (Fordtran)
Trial: 8363995
Drug: tropisetron (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tropisetron (5 mg/day; n = 115)
Trial: 8363995
Drug: optimal standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: optimal standard therapy (n = 116)
Trial: 20205490
Drug: Sitagliptin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin as initial combination therapy with metformin or pioglitazone
Trial: 20205490
Drug: Sitagliptin add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin add-on therapy
Trial: 20205490
Drug: Sitagliptin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin as add-on treatment to metformin
Trial: 20205490
Drug: Sitagliptin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin as add-on treatment to pioglitazone
Trial: 11878736
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 1:200,000 epinephrine and hyaluronidase 150 U ml(‐1) in a volume of 4 or 5 ml
Trial: 9779169
Drug: Prolonged antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged antibiotics (Unasyn and Aztreonam)
Trial: 9779169
Drug: Perioperative antibiotics
RxNorm normalized name: ENSURE SURGERY PERIOPERATIVE KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative antibiotics only (Unasyn)
Trial: 8154635
Drug: RG 12525
RxNorm normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG 12525 200 mg
Trial: 8154635
Drug: RG 12525
RxNorm normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG 12525 25 mg
Trial: 3163364
Drug: Low fat
RxNorm normalized name: Low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fat (31% of total kcal)/low cholesterol (193 mg/d) (LFLC)
Trial: 3163364
Drug: Low fat/usual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fat/usual cholesterol (504 mg/d) (LFUC)
Trial: 30246150
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg thrice daily)
Trial: 30246150
Drug: Ceftriaxone (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (2000 mg once daily)
Trial: 30246150
Drug: Paracetamol (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (1000 mg four times daily)
Trial: 30246150
Drug: Any combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any combination of metoclopramide, ceftriaxone, paracetamol
Trial: 27176931
Drug: Surgery +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery + Postoperative Radiotherapy (PORT) (median dose: 45 Grays)
Trial: 18771643
Drug: SPL7013 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPL7013 Gel
Trial: 16520686
Drug: Modafinil (100-400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (100-400 mg/day, median stable dose 300 mg/day)
Trial: 11145438
Drug: Interferon as
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon as maintenance after high-dose chemotherapy with stem cell support (NMSG 5/94)
Trial: 9181655
Drug: Tobramycin 160
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin 160 mg i.v. once daily for 2 days + Cefotaxime 1 g i.v. twice daily for 2 days followed by oral Cefadroxil 1 g twice daily for 10 days
Trial: 9181655
Drug: Cefotaxime 1
RxNorm normalized name: cefotaxime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 1 g i.v. twice daily for 2 days followed by oral Cefadroxil 1 g twice daily for 10 days
Trial: 3535021
Drug: CBS coated
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBS coated tablets
Trial: 3535021
Drug: CBS chewing
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBS chewing tablets
Trial: 3535021
Drug: CBS coated
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBS coated tablets and CBS chewing tablets
Trial: 27733181
Drug: Innovative psychological
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Innovative psychological therapy for depression (REFRAMED)
Trial: 22889722
Drug: Antidepressants (TCAs)
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (TCAs)
Trial: 22889722
Drug: Antidepressants (Miscellaneous)
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressants (Miscellaneous)
Trial: 10097932
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (CsA) at an initial dosage of 9.3 mg.kg‐1.day‐1 tapered to 7.0 mg.kg‐1.day‐1 for 12.5 +/- 4.0 months
Trial: 1768544
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate 30 mg kg‐1 with alfentanil 7.5 micrograms kg‐1
Trial: 1768544
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate 40 mg kg‐1 and Magnesium sulphate 30 mg kg‐1 with alfentanil 7.5 micrograms kg‐1
Trial: 31738342
Drug: Rotavirus Vaccine
RxNorm normalized name: rotavirus vaccine
DrugBank: Rotavirus vaccine (DB10276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotavirus Vaccine (RVV)
Trial: 28317676
Drug: Levofloxacin 1.5%
RxNorm normalized name: LEVOFLOXACIN 1.5% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 1.5% ophthalmic solution for 1 week postoperative
Trial: 28317676
Drug: Levofloxacin 1.5%
RxNorm normalized name: LEVOFLOXACIN 1.5% OPH SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 1.5% ophthalmic solution for 1 month postoperative
Trial: 24634627
Drug: Bilateral BoNT‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral BoNT‐A injections (25 U per muscle) into the masseter muscles only (group A)
Trial: 24634627
Drug: Bilateral BoNT‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral BoNT‐A injections into both the masseter and temporalis muscles (group B)
Trial: 22865871
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral prednisolone (0.5 mg/kg) for 3 days
Trial: 22865871
Drug: High-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oral prednisolone (2 mg/kg) for 3 days
Trial: 17442556
Drug: BacoMind (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BacoMind (300 mg for first 15 days, 450 mg for next 15 days)
Trial: 11193245
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg E2V + 2.5 mg MPA
Trial: 11193245
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg E2V + 5 mg MPA
Trial: 11193245
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg E2V + 2.5 mg MPA
Trial: 11193245
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg E2V + 5 mg MPA
Trial: 11193245
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg E2V increased to 2 mg after 6 months + 2.5 mg MPA
Trial: 11193245
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg E2V increased to 2 mg after 6 months + 5 mg MPA
Trial: 11193245
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg MPA
Trial: 11193245
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg MPA
Trial: 31315728
Drug: Transcutaneous neuromuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous neuromuscular electrical stimulation (twice a day, 30 minutes each time)
Trial: 15936036
Drug: Mannitol 20%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannitol 20%, 100 ml every 4 h for 5 days, tapered in the next 2 days
Trial: 12796019
Drug: FAC (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FAC (doxorubicin 500 mg/m², cyclophosphamide 50 mg/m², fluorouracil 500 mg/m²) every 3 weeks for six cycles
Trial: 12796019
Drug: CMF (methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMF (methotrexate 600 mg/m², cyclophosphamide 60 mg/m², fluorouracil 600 mg/m²) every 3 weeks for six cycles
Trial: 1888619
Drug: Individualised drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualised drug information wallet (leaflet group)
Trial: 30196448
Drug: 0.3 g
RxNorm normalized name: sorbitol 0.3 GM Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 g kg‐1 BM NaHCO3 (SBC3)
Trial: 30196448
Drug: 0.2 g
RxNorm normalized name: methionine 0.2 gram ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 g kg‐1 BM NaHCO3 (SBC2)
Trial: 27550876
Drug: Levofloxacin 500
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 500 mg once a day for 3 days after UDS
Trial: 24877603
Drug: CHoR protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHoR protocol (preoperative erythropoietin and iron therapy, intraoperative blood recycling device, lower hemoglobin trigger < 7 g/dl)
Trial: 22369484
Drug: Repeated near-infrared
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated near-infrared (NIR) light irradiation with fractionated administration of panitumumab-IR700 conjugate
Trial: 19808265
Drug: Nesiritide (2-microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nesiritide (2-microg/kg bolus plus 0.01-microg/kg-per-minute infusion for 4 to 6 hours, once or twice weekly for 12 weeks)
Trial: 19808265
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching placebo, once or twice weekly for 12 weeks)
Trial: 16060245
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy for unruptured cerebral aneurysms
Trial: 16060245
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy for aneurysms between 5 to 10 mm
Trial: 16060245
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy for aneurysms between 11 to 25 mm
Trial: 16060245
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy for aneurysms smaller than 5 mm
Trial: 16060245
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy for aneurysms between 5 to 10 mm (follow-up)
Trial: 16060245
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy for aneurysms between 10 to 24 mm (follow-up)
Trial: 16060245
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy overall
Trial: 16060245
Drug: Endovascular therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular therapy for a large basilar tip aneurysm
Trial: 6294004
Drug: Increased carbohydrate
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased carbohydrate intake from 200 to 400 g
Trial: 6294004
Drug: Increase of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase of dietary fibre to 50 g mainly as cereal fibre
Trial: 22057652
Drug: Thiamine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamine (300 mg/day)
Trial: 19605370
Drug: Type I
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Type I oral collagen
Trial: 16755104
Drug: Extended adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended adjuvant therapy, selection of responders using array-based techniques, combination therapy with signal transduction inhibitors
Trial: 10992952
Drug: Daily practice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily practice of three visual tasks (fixation, saccade, and distractor conditions) for 3 to 8 weeks
Trial: 8865709
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml oral water
Trial: 8865709
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml refreshing drink
Trial: 1624025
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate 1.88 mg
Trial: 6084920
Drug: Increased concentration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased concentration of IgE antibodies
Trial: 6084920
Drug: Specific IgG
RxNorm normalized name: Mold specific IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific IgG antibodies towards TR
Trial: 6084920
Drug: Presence of
RxNorm normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presence of specific IgG antibodies and strong specific cellular immune response
Trial: 28118549
Drug: Lower-target group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-target group (80 to 110 mg/dL)
Trial: 28118549
Drug: Higher-target group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-target group (150 to 180 mg/dL)
Trial: 26009989
Drug: 3 weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 weeks of oral antibiotic treatment
Trial: 26009989
Drug: 6 weeks
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 weeks of oral antibiotic treatment
Trial: 21757386
Drug: Control periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control periodontal therapy (CPT)
Trial: 21757386
Drug: Intensive periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive periodontal therapy (IPT) in type 2 DM
Trial: 14747190
Drug: GnRH analogue
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH analogue (3.75 mg/28 days leuprolide acetate depot) with raloxifene (60 mg/day)
Trial: 2898025
Drug: Intensified diabetic
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified diabetic control with continuous subcutaneous insulin infusion (CSII)
Trial: 30370503
Drug: Hypothetical above
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothetical above average pharmacogenetic response to smoking cessation medication
Trial: 30370503
Drug: Hypothetical below
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothetical below average pharmacogenetic response to smoking cessation medication
Trial: 28969404
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea catechins (600 mg daily for 1 year)
Trial: 26242893
Drug: Intravenous ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ibandronate (6mg)
Trial: 26242893
Drug: Single-dose radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose radiotherapy (8 Gy)
Trial: 18418314
Drug: Antioxidant therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant therapy, hydration regimens, choice of contrast agents
Trial: 17165278
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate DPI 100 microg twice daily
Trial: 17165278
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate DPI (both doses)
Trial: 11069325
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy (lansoprazole 30 mg o.d. plus amoxicillin 750 mg b.d.)
Trial: 11069325
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy plus ecabet sodium (1 g b.d.)
Trial: 11069325
Drug: Dual therapy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual therapy plus ecabet sodium (2 g b.d.)
Trial: 9059199
Drug: Ketoprofen 1
RxNorm normalized name: ketoprofen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 1 mg kg-1 i.v. after induction followed by an infusion of ketoprofen 1 mg kg-1 over 2 h
Trial: 8419248
Drug: Propofol (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.5 mL = 15 mg)
Trial: 27130793
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy plus radiation therapy to 70 Gy
Trial: 22067254
Drug: MagPro™ (Mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MagPro™ (Mg cream)
Trial: 19018977
Drug: Atropine 0.5
RxNorm normalized name: homatropine 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.5 mg
Trial: 7153153
Drug: Atropine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 1.0 mg
Trial: 28252875
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac (0.1%) four times a day for 7 days before surgery and discontinued 30 days after surgery
Trial: 28252875
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac (0.1%)
Trial: 23144450
Drug: Pegloticase 8
RxNorm normalized name: pegloticase 8 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegloticase 8 mg biweekly
Trial: 23144450
Drug: Pegloticase 8
RxNorm normalized name: pegloticase 8 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegloticase 8 mg monthly
Trial: 21448308
Drug: Flurbiprofen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen (2 x 100 mg) and tramadol (4 x 100 mg)
Trial: 21448308
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received tramadol (4 x 100 mg)
Trial: 19257824
Drug: Ibandronate (IBN)
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate (IBN) 2 mg intravenously every 3 months
Trial: 16015459
Drug: Autogenic training
RxNorm normalized name: Autogene cevumeran
DrugBank: Autogene cevumeran (DB17497)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autogenic training (AT) for 10 weeks, with weekly sessions and daily practice at home
Trial: 12581053
Drug: Boost intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Boost intervention in conservative treatment
Trial: 20948238
Drug: Nilvadipine 4
RxNorm normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine 4 mg/day for ≥30 months
Trial: 20948238
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (tocopherol nicotinate 300 mg/day, helenien 15 mg/day, or no medication) for ≥30 months
Trial: 20948238
Drug: Nilvadipine 4
RxNorm normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine 4 mg/day for total observational period
Trial: 16458337
Drug: Co-trimoxazole prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole prophylaxis (sulphamethoxazole 800 mg/trimethoprim 160 mg daily)
Trial: 1451052
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 5‐fluorouracil (1000 mg/m2 for 48 hours)
Trial: 1451052
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of 5‐fluorouracil (500 mg/m2 x 2 in 48 hours)
Trial: 1451052
Drug: Bolus injection
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus injection of 5‐fluorouracil
Trial: 17966969
Drug: Metformin (M,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (M, n = 13)
Trial: 17966969
Drug: Gliclazide (G,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide (G, n = 13)